Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S; New Approaches to Brain Tumor Therapy CNS Consortium. Olivi A, et al. Among authors: barker f. J Clin Oncol. 2003 May 1;21(9):1845-9. doi: 10.1200/JCO.2003.09.041. J Clin Oncol. 2003. PMID: 12721262 Clinical Trial.
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J. Chiocca EA, et al. Among authors: barker f. Mol Ther. 2004 Nov;10(5):958-66. doi: 10.1016/j.ymthe.2004.07.021. Mol Ther. 2004. PMID: 15509513 Free article. Clinical Trial.
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.
Grossman SA, Romo CG, Rudek MA, Supko J, Fisher J, Nabors LB, Wen PY, Peereboom DM, Ellingson BM, Elmquist W, Barker FG, Kamson D, Sarkaria JN, Timmer W, Bindra RS, Ye X. Grossman SA, et al. Neuro Oncol. 2020 Oct 14;22(10):1422-1424. doi: 10.1093/neuonc/noaa142. Neuro Oncol. 2020. PMID: 32506123 Free PMC article. No abstract available.
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K. Pelloski CE, et al. Among authors: barker fg 2nd. J Clin Oncol. 2007 Jun 1;25(16):2288-94. doi: 10.1200/JCO.2006.08.0705. J Clin Oncol. 2007. PMID: 17538175
Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project.
Chang SM, Parney IF, McDermott M, Barker FG 2nd, Schmidt MH, Huang W, Laws ER Jr, Lillehei KO, Bernstein M, Brem H, Sloan AE, Berger M; Glioma Outcomes Investigators. Chang SM, et al. Among authors: barker fg 2nd. J Neurosurg. 2003 Jun;98(6):1175-81. doi: 10.3171/jns.2003.98.6.1175. J Neurosurg. 2003. PMID: 12816260
Improving resection of malignant glioma.
Barker FG 2nd, Chang SM. Barker FG 2nd, et al. Lancet Oncol. 2006 May;7(5):359-60. doi: 10.1016/S1470-2045(06)70669-6. Lancet Oncol. 2006. PMID: 16648038 No abstract available.
404 results